Miyahira Andrea K, Simons Jonathan W, Soule Howard R
Prostate Cancer Foundation, Santa Monica, California.
Prostate. 2016 Sep;76(12):1037-52. doi: 10.1002/pros.23193. Epub 2016 Jun 8.
The 22nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat was convened in Washington, D.C. from October 8 to 10, 2015. This event is the foremost scientific conference in the world focusing on basic, translational, and clinical prostate cancer research with the highest potential for accelerating the understanding of prostate cancer biology and improving the lives and outcomes of prostate cancer patients. Topics highlighted during the 2015 Retreat included: (i) new strategies and treatments for localized high-risk, hormone-naïve, oligometastatic, castrate-resistant, and treatment-refractory prostate cancer settings; (ii) the biology and genomics of tumor heterogeneity and tumor evolution; (iii) new understandings on the mechanisms and targeting of oncogenic drivers of prostate cancer; (iv) bioengineering of novel therapies and drug delivery methods; (v) innovative approaches to tumor immunotherapy; (vi) emerging molecular imaging technologies with improved sensitivity and specificity; and (vii) advancements in prognostic and predictive biomarkers and precision medicine strategies. Prostate 76:1037-1052, 2016. © 2016 Wiley Periodicals, Inc.
第22届前列腺癌基金会(PCF)科学研讨会于2015年10月8日至10日在华盛顿特区召开。该活动是世界上最重要的科学会议,专注于基础、转化和临床前列腺癌研究,在加速对前列腺癌生物学的理解以及改善前列腺癌患者的生活和治疗结果方面具有最大潜力。2015年研讨会重点讨论的主题包括:(i)针对局限性高危、激素初治、寡转移、去势抵抗和治疗难治性前列腺癌的新策略和治疗方法;(ii)肿瘤异质性和肿瘤进化的生物学及基因组学;(iii)对前列腺癌致癌驱动因素的机制和靶向的新认识;(iv)新型疗法和药物递送方法的生物工程;(v)肿瘤免疫疗法的创新方法;(vi)具有更高灵敏度和特异性的新兴分子成像技术;以及(vii)预后和预测生物标志物及精准医学策略的进展。《前列腺》76:1037 - 1052,2016年。© 2016威利期刊公司。